NEUROCRINE BIOSCIENCES INC
Close on Oct 19, 2026
- Market cap
- $14.27B
- P/E (TTM)
- 20.1
- Dividend yield
- –
Earnings
Next report expected Oct 27, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 30, 2026 | After market close | $959.00M | $1.39 | $2.85 |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | After market close | $814.50M | $1.91 | $1.94 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 11, 2026 | After market close | $805.50M | $1.48 | $1.88 |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 28, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 30, 2025 | After market close | $687.50M | $1.06 | $1.65 |
| Q1 FY2025 Ended Mar 31, 2025 | May 5, 2025 | After market close | $572.60M | $0.08 | $0.70 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 6, 2025 | After market close | $627.70M | $1.00 | $1.69 |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 30, 2024 | Before market open | $622.10M | $1.24 | $1.81 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 1, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 7, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Jul 30, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| IPR&D | Full Year 2026 | $23.00M | Raised |
| GAAP R&DGAAP | Full Year 2026 | $1.28B to $1.33B | Lowered |
| GAAP SG&AGAAP | Full Year 2026 | $1.58B to $1.60B | Raised |
| GAAP Amortization of Acquired Intangible AssetsGAAP | Full Year 2026 | $85.00M to $90.00M | Lowered |
| Non-GAAP R&Dnon-GAAP | Full Year 2026 | $1.14B to $1.19B | Lowered |
| Non-GAAP SG&Anon-GAAP | Full Year 2026 | $1.33B to $1.35B | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Neurocrine Biosciences filed with the SEC
Neurocrine Biosciences Reports Second-Quarter 2026
Results of operations · EX-99.1 to Form 8-K
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
Material agreement · Acquisition or disposition completed · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Neurocrine Biosciences Reports First-Quarter 2026
Results of operations · EX-99.1 to Form 8-K
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025
Results of operations · EX-99.1 to Form 8-K
Neurocrine Biosciences Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Neurocrine Biosciences Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Neurocrine Biosciences Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Neurocrine Biosciences Announces Commercial Availability of
Other events · EX-99.1 to Form 8-K
Neurocrine Biosciences Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
Results of operations · EX-99.1 to Form 8-K
Neurocrine Biosciences Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
Results of operations · EX-99.1 to Form 8-K
Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
Results of operations · EX-99.1 to Form 8-K
Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
Results of operations · EX-99.1 to Form 8-K
Neurocrine Biosciences Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Neurocrine Biosciences Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Neurocrine Biosciences Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Neurocrine Biosciences Announces Repurchase of Convertible Notes
Other events · EX-99.1 to Form 8-K
Neurocrine Biosciences Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022
Results of operations · EX-99.1 to Form 8-K
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2021
Results of operations · EX-99.1 to Form 8-K
Neurocrine Biosciences Reports Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K